Lisocabtagene Maraleucel Shows Deep, Durable Responses in Patients with Relapsed or Refractory MZL After at Least Two Previous Lines of Systemic Therapy By Ogkologos - February 19, 2026 231 0 Facebook Twitter Google+ Pinterest WhatsApp Findings from the marginal zone lymphoma cohort of the TRANSCEND FL study Source RELATED ARTICLESMORE FROM AUTHOR Comprehensive Genomic Profiling with Subsequent Molecularly Guided Therapy Improves Outcomes Over Platinum-based Chemotherapy in Previously Untreated, Unfavourable CUP NCI and CRUK Take on Cancer’s Toughest Problems Tebentafusp Continues to Provide Long-Term OS Benefit in Previously Untreated Patients with Unresectable or Metastatic Uveal Melanoma MOST POPULAR Surgery for Recurrent Ovarian Cancer Does Not Improve Survival December 10, 2019 Born Blind With 50% Chance Of Survival, 20-Year-Old Musician Defied All... November 1, 2021 Techniques for Successful Glucose Daddies and Babies Relationships September 4, 2022 Mom Of Three Fought Breast Cancer, Drought, And Australia Bushfires In... January 8, 2020 Load more HOT NEWS Understanding FDA Emergency Use Authorization Jimmy Carter Signed This Treaty Demanding An End To Violence Against... This Amazing Woman Can Smell Alzheimer’s, Parkinson’s, and Cancer Years Before... New Study Says At-Home Cancer Care May Lead to Fewer Hospitalizations...
